Last updated: July 20, 2026
Sanofi-Aventis U.S. LLC sued Hong Kong King-Friend Industrial Company Ltd. in the U.S. District Court under case number 1:20-cv-01547. No party, court, filing dates, asserted patents, asserted claims, procedural posture, merits rulings, or settlement terms are provided in the input. Without those case-record particulars, a complete and accurate litigation analysis cannot be produced.
What patents and claims were asserted in Sanofi-Aventis U.S. LLC v. Hong Kong King-Friend Industrial Company Ltd. (1:20-cv-01547)?
No asserted patents or claim(s) are included in the provided information.
Which IP rights were at issue: patents, trade secrets, or trademarks?
No infringement theories or IP categories are stated in the provided information.
Which product(s) and active ingredient(s) were implicated?
No drug, API, intermediate, or formulation is identified in the provided information.
What is the procedural posture for 1:20-cv-01547, and what happened next?
No docket milestones are provided (complaint filing date, answer/MTD deadlines, claim construction, discovery schedule, summary judgment, trial, or post-judgment events).
Was there a motion to dismiss, preliminary injunction, or transfer?
No motions or rulings are included in the provided information.
Were there amended complaints or counterclaims?
No amendments or counterclaims are included in the provided information.
When did the litigation start, and what deadlines drove the case timeline?
No filing date, service date, scheduling order date, or key deadline dates are included in the provided information.
What were the key dates for pleadings and hearings?
No hearing dates or briefing dates are included in the provided information.
Did the case resolve early via settlement or dismissal?
No resolution mechanism is stated in the provided information.
How strong was Sanofi’s position based on claim construction, expert discovery, or summary judgment outcomes?
No merits outcomes or evidentiary findings are provided, so strength cannot be evaluated.
Were any patents found valid or infringed?
No validity or infringement determinations are included in the provided information.
Were any defenses credited (non-infringement, invalidity, exhaustion, estoppel)?
No defense positions or rulings are included in the provided information.
What is the impact of 1:20-cv-01547 on generic or biosimilar entry risk in the U.S.?
No link to an Orange Book-listed product, FDA proceeding, ANDA/BLA litigation, or Paragraph IV theory is provided.
Was the suit connected to an ANDA or Section 505(b)(2) filing?
No FDA pathway linkage is included in the provided information.
Did the dispute involve contract manufacturing, API supply, or infringement of process patents?
No manufacturing or supply-chain allegation is included in the provided information.
What settlement or consent outcomes were reached, and what did they require?
No settlement terms, consent judgments, licensing agreements, or covenants are provided in the input.
Was there a permanent injunction or limited injunction?
No injunction details are included in the provided information.
Did the parties enter a license (paid-up, running royalties, or field-of-use limits)?
No licensing outcomes are included in the provided information.
How does the Hong Kong King-Friend Industrial Company Ltd. matter compare with similar Sanofi enforcement actions?
No comparator cases or enforcement patterns are provided in the input.
Do other Sanofi litigations show a consistent asserted-portfolio strategy?
No portfolio strategy is provided in the input.
What jurisdictions and enforcement targets does Sanofi typically use?
No enforcement geography is provided in the input.
Key Takeaways
- The case identifier is provided (1:20-cv-01547), but the input contains no docket facts needed for an accurate litigation summary or legal analysis.
- A substantive patent- and procedure-driven assessment (asserted IP, timeline, rulings, defenses, settlement terms, and business impact) cannot be constructed from the provided information.
FAQs
- What court and judge handled 1:20-cv-01547?
- Which patents were asserted by Sanofi-Aventis in this case?
- Did Sanofi seek a preliminary injunction or temporary restraining order?
- Was there a Paragraph IV or FDA ANDA/BLA linkage to the lawsuit?
- What was the final disposition of the case (dismissal, judgment, settlement)?
References
- PACER case record for Sanofi-Aventis U.S. LLC v. Hong Kong King-Friend Industrial Company Ltd., No. 1:20-cv-01547.
